News | March 11, 2025
Syngene acquires first US biologics facility for $36.5 million
Overall investment in the US facility is estimated around US$50 million
Overall investment in the US facility is estimated around US$50 million
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The Alathur facility specializes in the production of Cephalosporin antibiotics
Subscribe To Our Newsletter & Stay Updated
